APA (7th ed.) Citation

Tesch, H., Marmé, F., & Schneeweiss, A. (2019). Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. International journal of cancer, 144(4), . https://doi.org/10.1002/ijc.31738

Chicago Style (17th ed.) Citation

Tesch, Hans, Frederik Marmé, and Andreas Schneeweiss. "Efficacy and Safety of Everolimus Plus Exemestane in Postmenopausal Women with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Locally Advanced or Metastatic Breast Cancer: Results of the Single-arm, Phase IIIB 4EVER Trial." International Journal of Cancer 144, no. 4 (2019). https://doi.org/10.1002/ijc.31738.

MLA (9th ed.) Citation

Tesch, Hans, et al. "Efficacy and Safety of Everolimus Plus Exemestane in Postmenopausal Women with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Locally Advanced or Metastatic Breast Cancer: Results of the Single-arm, Phase IIIB 4EVER Trial." International Journal of Cancer, vol. 144, no. 4, 2019, https://doi.org/10.1002/ijc.31738.